Jerusalem, Israel, 30 April 2018 â€“ NovellusDx, the leader in functional genomics, today announced it has completed an equity financing of $6 million. The financing round is with the participation of Helsinn Investment Fund S.A. SICAR, part of Helsinn Group, a leading cancer care company, Bio Capital Impact Fund, and Windham Venture Partners. This adds to the nearly $17 million already raised by the company.
â€œWe are excited to invest in NovellusDx and support their aim to lead the functional genomics revolution,â€ said Roberto De Ponti, Head of New Venture and Strategic Investment at Helsinn International Services sarl. â€œNGS has revolutionised cancer care and now we have the opportunity to take it one step further to functionally test the mutations found and their response to drugs. This is the true promise of personalised medicine in cancer.â€
â€œThe additional funds will allow us to accelerate the execution of our strategy, move into commercialisation and enable us to meet the need for functional oncology worldwide. This funding will also support continuing development and enhancement of NovellusDxâ€™s technology using our excellent R&D team in Jerusalemâ€, said Haim Gil-Ad, CEO of NovellusDx.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO added, â€œIsrael is a hub for technological innovation, including in the life sciences, and NovellusDx is a premier example of that. We are excited to help bring its technology to the market and envision a deeper collaboration going forward.â€
Adam Fine, Co-founder and Managing Director of Windham Venture Partners, remarked, â€œNovellusDx has developed a unique solution to a large unmet need in cancer by completing the â€˜treatment stackâ€™: biopsy, NGS, functional mutation testing and drug response. The technology can open up the full potential of NGS and cancer therapeutics.â€
Helen Fisher, CEO and Managing Director of Bio Capital Impact Fund, said â€œWe at Bio Capital Impact Fund are excited to join other high-calibre investors and provide active support for NovellusDX. NovellusDx has the potential to revolutionise personalised cancer treatment and significantly improve the drug development process. By being able to stratify patients based on functional analysis of their individual genetic mutations quickly and cost-effectively, NovellusDxâ€™s technology could reduce the cost of bringing new drugs to market and deliver better outcomes for patients.â€
“As an early investor in NovellusDx, we are very pleased to welcome firms and strategic partners of this quality”, said Erez Chimovits, partner at OrbiMed. “This new coalition further validates the significant opportunities ahead for NovellusDx.”
About Helsinn Investment Fund S.A., SICAR
The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinnâ€™s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients. Drawing on Helsinnâ€™s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.
For more information, visit www.helsinninvestmentfund.com
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialisation of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.
To learn more about Helsinn Group please visit www.helsinn.com
Founded in 2006, Windham is a New York City-based venture capital firm focused on healthcare, with a particular emphasis on medical technology (devices and diagnostics) and health care information technology (HCIT). Windham partners with entrepreneurs and companies that are commercialising game-changing technologies to serve unmet needs, improve the lives of large numbers of patients, and yield robust returns for its investors.
To learn more about Windham please visit www.windhamvp.com
Bio Capital Impact Fund (BCIF) is an absolute return evergreen global fund investing in innovative companies in Health, Agricultural and Industrial biotechnology sectors. BCIF aims to create value â€“ for its investors and for the world. BCIF is an active investor, helping companies to successfully commercialise their technologies by contributing not only cash but also the expertise, experience and global networks of its team.
To learn more about BCIF please visit www.bcif.com.au
NovellusDxâ€™s mission is to provide functional information about mutations and their responses to drugs so that oncologists can treat patients with precision therapies and bio-pharmaceutical companies can develop drugs more effectively. The NovellusDx approach is to monitor the functional effects of mutations and observe the effects of drugs, drug combinations and drug candidates on the activity level caused by the mutations. NovellusDxâ€™s headquarters and research and development operations are based in Jerusalem, Israel.
To learn more about NovellusDx please visit www.novellusdx.com
Thank you for your form submission, we will get in contact with you shortly.